Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Synageva BioPharma

Request full access

Discovering, developing, and delivering innovative medicines for people living with rare diseases of high unmet medical need

Lexington, United StatesFounded 1996Biotech & Life Sciences

About Synageva BioPharma

Synageva BioPharma Corp. operated as a biopharmaceutical firm concentrated on the discovery, development, and commercialization of therapeutic products for patients with rare and devastating diseases. The company was originally incorporated as AviGenics, Inc. in 1996, founded by Dr. Robert Ivarie of the University of Georgia. A significant shift in strategy occurred in 2008 when Sanj K. Patel, a former executive at Genzyme Corporation, was brought in as CEO. Patel refocused the company on developing treatments for rare diseases, moving away from its initial business of creating bio-similar drugs.

The company's core asset was a proprietary technology platform utilizing a transgenic Gallus expression system to produce recombinant DNA proteins in the egg whites of genetically engineered chickens. This method allowed for the creation of proteins with specific glycan structures crucial for targeted cell delivery. Synageva went public on the NASDAQ in November 2011 through a reverse merger with Trimeris, Inc. The company’s primary business model was centered on developing a pipeline of protein-based therapies for rare diseases with unmet medical needs and bringing them to market.

Synageva's lead product candidate was Kanuma® (sebelipase alfa), an enzyme replacement therapy designed to treat Lysosomal Acid Lipase Deficiency (LAL-D), a rare and often fatal genetic disorder. LAL-D causes a buildup of fatty material in the liver, blood vessels, and other tissues. Before its acquisition, Synageva was preparing for the global launch of Kanuma, which had received priority review status from the FDA and accelerated assessment from the European Medicines Agency. In addition to Kanuma, the company's clinical pipeline included SBC-103, an enzyme replacement therapy for patients with mucopolysaccharidosis IIIB (MPS IIIB), and over 30 preclinical programs.

In a landmark deal for the biotech sector, Alexion Pharmaceuticals announced its acquisition of Synageva in May 2015 for approximately $8.4 billion. The acquisition, which was unanimously approved by both boards and completed in June 2015, was a strategic move by Alexion to strengthen its global leadership in rare diseases and diversify its revenue streams. The price represented a premium of about 140% over Synageva's share price at the time, underscoring the perceived value of its pipeline, especially Kanuma. Following the acquisition, the FDA approved Kanuma in December 2015.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1996
Headquarters
Lexington, United States
Listing
IPO 2011
Employees
19
Open positions
None listed
Dealroom signal
25.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2015 $8.4B $8.4B Alexion Pharmaceuticals —
POST IPO EQUITYOther financing Jan 2015 $308M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Synageva BioPharma website traffic

Latest recorded traffic for Synageva BioPharma is 2.5K monthly website visits, up 900% over the last three months. Synageva BioPharma's team declined 9.5% over the past year.

Latest monthly visits2.5K 3-month web change+900% 1-year team growth-9.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Synageva BioPharma in the Lexington ecosystem

Live from Dealroom

The Synageva BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later8 investors entered at this stage

  • Cordova Ventures
  • Fuqua Ventures
  • Kitty Hawk Capital
  • Four Partners
  • Tullis Health Investors
  • New Leaf Venture Partners
  • Yasuda Enterprise Development
  • Covera Ventures

Other known investors1 additional known investor

  • Alexion Pharmaceuticals
Team profiled 26 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇺🇸 United States22.2%
🇧🇷 Brazil11.1%
🇸🇦 Saudi Arabia11.1%
🇩🇪 Germany11.1%
🇨🇭 Switzerland11.1%
Top 5 of 8 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Synageva BioPharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synageva BioPharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.